Sell Data to AI
Home Log in AI Data Value Score Pricing API documentation MCP server for AI assistants 26 US company lists Niche lists
For brokers
The Sell Data to AI Rules How to become an AI data broker Data broker business model Buyer programs compared Qualify a company AI training data companies
For data companies
Firmographic data providers Company data API
Seller guides
How to sell data to AI companies Is it legal? Anonymize before selling Score, then make it safe to sell FAQ and glossary
Score any company Check your own company
For brokers and data companies

List of US pharmaceutical companies, scored by data value

Last updated: 8 October 2026. Buyer facts as published, checked 7 October 2026.

A revenue ranking tells you who is big. A broker, or a sourcing team at an AI data company, needs a different order: which companies generate the records AI buyers want, which of those records the company actually owns, and who inside can say yes. This page maps US pharma and its service ecosystem in that order, then shows how to work our scored list of US labs, CROs and life-science companies.

5 segmentsbig pharma, specialty, generics, CDMO and CMO, pharma services
6 record familiesquality, regulatory, batch, safety, medical information, support
From $199one-time: the top 3,000+ by AI Data Value Score, selected from 22,954 US domains in this sector of our index
9 factor groupsbehind every AI Data Value Score, activity status included

Found a target? Qualify it against micro1 and Mode rules in about 20 seconds.

The data AI labs pay most for, identified for every company

Not all company data is worth the same. Our research shows AI labs pay most for the records of real work, held in the systems below. We identify which of these systems each company runs, and it is one of the most important factors in the AI Data Value Score.

Work tickets and internal wikiJira, Confluence
Customer support ticketsZendesk, Intercom
CRM recordsSalesforce, HubSpot
Calls and meetingsZoom, Gong
Contracts and documentsDocuSign, Box
Design filesFigma, Miro
Finance and ERP recordsNetSuite, QuickBooks
Code with historyGitHub, GitLab
Work email and documentsMicrosoft 365, Google Workspace
HR and recruiting recordsWorkday, Greenhouse
Training and course contentLearning platforms, course libraries
Fleet and sensor dataFleet and machine data
Clinical and lab systemsPatient and lab records
Human-era archivesYears of records written before 2023

Every company comes with the systems we identified, shown as tags. Company level only: we show which systems a company runs, never what is inside them.

What the top 4,200 labs, CROs and life-science companies hold

Share of the 4,200 companies in this list with each data type. Among them, 15% run systems for CRM records, 11% for contracts and documents, 10% for work tickets and internal wikis, and 64% have been online for 10 years or more before 2023.

84%run data systems we identified
29%run systems beyond work email, such as CRM, tickets or contracts
64%online 10+ years before 2023 (human-era archives)
27%online 20+ years before 2023

Data types, by share of companies

Work email and documents83% · 3,492
CRM records15% · 621
Contracts and documents11% · 464
Work tickets and internal wiki10% · 418
Calls and meetings8% · 330
Customer support tickets2% · 103
Finance and ERP records2% · 69
Design files2% · 65
HR and recruiting records<1% · 33
Clinical and lab systems<1% · 25
Training content<1% · 4
Code with history<1% · 1

Most common systems

Microsoft 36564%Google Workspace27%Jira / Confluence9%DocuSign9%HubSpot9%Salesforce7%Zoom6%Box2%Zendesk2%Webex1%NetSuite1%Slack1%Notion1%Miro1%

Data signals on their websites

Lab, study and R&D records100%
Work email and documents83%
Recruiting and hiring records35%
Order and transaction records30%
Support tickets and chat transcripts25%
CRM and sales records25%
Knowledge base, SOPs and documentation24%
Customer accounts and portal activity21%

Counted over the companies a buyer gets in this list: verified active, checked for fit with the industry, highest AI Data Value Score first. Company level only: we show which systems a company runs, never what is inside them.

Narrower niche lists for this field

Niche lists go deeper than a sector list. Every company domain is verified active, each company was checked for fit with the niche, and companies are ranked by the AI Data Value Score. $2,500 per list, or $9,900 for 90 days of exclusive access.

Start here

Why a revenue-ranked pharma list is the wrong starting point

Search for a list of pharmaceutical companies in the USA and you get the same names in the same order: the largest drug makers by sales, then a long tail sorted alphabetically. That list answers an investor's question, or a job seeker's. It does not answer the question a data broker or a partnership team at an AI data company is asking, which sounds more like this: where is there a large, owned, well-documented record of expert work, and is there someone at that company who can approve licensing a copy of it?

Pharma is an unusually rich place to ask. The industry runs on written procedure. Every batch is recorded step by step. Every deviation is investigated and closed with a documented root cause. Every adverse event report is triaged, coded and assessed, and every question from a physician gets a referenced answer. Regulators require much of this paperwork, so it exists, it is structured, and it goes back years. That is the kind of record AI buyers describe wanting: long, connected histories of how specialists reason and decide.

It is also an unusually hard place to close a deal. A large share of what pharma companies hold is patient data, a trade secret, or content that belongs to a client or a sponsor. Separating the record that might be licensable from the record that never will be is most of the work, and the split changes by segment. So this page goes segment by segment, then record by record, and then lists the questions to put in front of counsel before anyone mentions a buyer.

What this page is not. It is not a complete directory of US drug makers, and it does not rank anyone by size or sales. The company list closest to pharma is our US labs, CROs and life-science companies list, one of 26 US industry lists we sell. A pharmaceutical company outside it can be scored one at a time in the AI Data Value Score demo or through the API.
Five segments

The five segments of US pharma, and how each looks to a data buyer

One industry label covers very different businesses. What a company makes decides which records it keeps. How big it is decides who signs. The fit labels below are our reading for a broker's time, not a buyer's verdict.

Long path to yes

Big pharma

What it is
Global companies that discover, develop, make and sell their own medicines, with staff in many countries and every function in house.
Records it keeps
The whole chain, from discovery notebooks and trial operations to global safety databases, manufacturing networks and field sales CRM.
Practical fit
The deepest records and the most desks to cross. Central data governance, internal AI programs and global privacy teams all review a licensing idea, and a company this size can approach AI labs directly.
Depends on scope

Specialty pharma

What it is
Companies focused on a few therapeutic areas or product types, such as rare disease, dermatology or injectables. Many outsource manufacturing to CDMOs and trials to CROs.
Records it keeps
Regulatory correspondence, medical affairs and medical information, launch planning, and oversight of the vendors and contract manufacturers it relies on.
Practical fit
Reachable leadership and fewer systems, but the core of its record often touches patients or partners, so scope needs care from the first conversation.
Depends on scope

Generics

What it is
Companies that make off-patent medicines at volume, filing abbreviated applications that rest on bioequivalence rather than new clinical trials.
Records it keeps
Batch records, quality control lab results, stability studies, investigations and corrective actions, and supply chain history across many products.
Practical fit
A strong quality and manufacturing record. Formulations and process parameters are the competitive core, though, so the trade secret question comes first.
Own records only

CDMO and CMO

What it is
Contract development and manufacturing organizations make other companies' products: tech transfer, scale-up, commercial runs, fill and finish, packaging.
Records it keeps
Batch records, deviations, change controls, client audits, tech transfer packages and a large SOP library.
Practical fit
Rich operating records, often at mid-size. Much of it describes a client's product under a quality agreement. What the CDMO owns outright is usually its own procedures, training and how it runs its quality system.
Often most practical

Pharma services

What it is
The wider ecosystem around drug makers: CROs, central and bioanalytical labs, testing labs, regulatory and quality consultancies, pharmacovigilance and medical information providers, packaging and labeling specialists, validation firms, and the companies that make software and instruments for labs and quality teams.
Records it keeps
Project histories, method know-how, SOPs and training programs, support tickets, proposals and the internal discussion behind each service.
Practical fit
Often the best use of a broker's time. Many are mid-size firms that own their methods and their support history, sit inside the team sizes buyer programs publish, and have a leader who can decide without a committee.

A rule of thumb that holds across all five: the further a company sits from the patient and the molecule, the more of its record it owns outright. A CRO's study data belongs to the sponsor, but its SOPs, training program and the way it runs projects are its own. A testing lab's results belong to its clients, but its method validation know-how and its support history are its own. A software vendor to quality teams may own almost everything it holds, apart from customer content. When you sort a prospect list, sort by that distance first and by company size second.

The records

Six record families pharma generates, and who usually owns each

These are the records that come up when sourcing teams describe what they want from regulated industries. Ownership here is the usual pattern, not a rule: each company's contracts decide it.

Record familyTypical systemsWhat is insideUsually owned byWhy AI buyers care
Quality systemsElectronic QMS, document control, training managementSOPs, deviations, investigations, corrective and preventive actions, change controls, audit findings, training recordsThe company, for its own procedures. The client, for product records at a CDMO or CROAn investigation is written expert reasoning: a problem, the evidence, a conclusion and a fix
Regulatory submissionsRegulatory information management, publishing tools, document managementApplications, amendments, annual reports, answers to agency questions, labelingThe sponsor that filed them, even when a consultancy or CRO wrote themLong technical writing in a strict structure, plus the questions an agency asked and how they were answered
Manufacturing batch recordsMES, electronic or paper batch records, ERPMaster and executed batch records, in-process checks, equipment logs, line clearance, exceptionsThe product owner, for product data. The manufacturer, for its own equipment and methodsStep-by-step procedure with checks and exceptions, a close match for process and agent training
PharmacovigilanceSafety databases, case intake, literature screeningAdverse event cases, narratives, coding, causality assessments, periodic safety reports, signal reviewsThe company that holds the marketing authorization. Service providers process cases for itA repeated expert workflow from intake to assessment. Also full of patient health information
Medical informationMedical information systems, contact center tools, content librariesQuestions from physicians, pharmacists and patients, standard response documents, referencesThe company that markets the product. Vendors often run it under contractQuestion and referenced answer pairs written by specialists. Inquiries carry personal and sometimes health data
SupportHelpdesk, CRM, customer portals, knowledge basesCustomer and technical support tickets, order issues, instrument and software support, how-to articlesUsually the company itselfLong, specialist conversations about real problems, and usually the easiest family to scope and de-identify

General patterns, not legal conclusions. Quality agreements, master services agreements, licensing deals and consent forms decide who owns what at a given company.

Support records are the quiet winner

Brokers new to pharma go straight for the regulated record: submissions, batch records, safety cases. Those are the most impressive and the hardest to license. The record that moves most easily is often the plainest one. A company that sells instruments, reagents, software or testing services to labs has years of support tickets in which specialists explain a failed run, a calibration drift or a validation question to another specialist. Those threads are the company's own, they rarely contain patient data, and they can be scoped by product line and date. In the free labs preview, support tickets and chat transcripts often appear among the likely data assets.

Raw records versus evaluations

Raw records are the start, not the whole value. Practitioners say evaluations are worth about 10 times raw data, and full environments reach six to eight figures. Pharma workflows translate well into both. A deviation investigation, a safety case or a medical information response has a clear input, a documented expert process and an output a reviewer can check. For a data company, that means a pharma services firm may be worth more as a partner whose specialists help build and grade tasks than as a one-time seller of an archive. For a broker, it means the introduction is worth framing around the company's expertise, not only its files.

Off limits until counsel says otherwise

Patient data, trade secrets and regulated submissions: questions for counsel

None of this is legal advice. These are the questions to put to the company's own lawyer, and to yours, before anyone drafts a manifest. If the honest answer to any of them is "we do not know", the record stays out of scope.

Patient and health data

  • Does the record contain information about trial participants, patients in safety cases, or patients who contacted medical information or a support program?
  • Which rules cover it: HIPAA, state health privacy laws, the consent forms participants signed, or GDPR for sites outside the US?
  • Can free-text narratives be de-identified at all, or must the whole record family be excluded?

Trade secrets and know-how

  • Does the record reveal formulations, process parameters, yields, impurity profiles or supplier terms the company keeps confidential?
  • Could licensing a copy, even a de-identified one, weaken trade secret protection?
  • Who inside decides what counts as know-how, and is that decision written down?

Regulated submissions

  • Who owns each submission and the agency correspondence: the company, a sponsor, or a co-development partner?
  • Do partner agreements or confidentiality terms limit reuse of submission content?
  • For a consultancy that wrote submissions for clients, what does each engagement letter say about work product?

Client and sponsor data

  • For a CRO, CDMO or lab: what do the master services and quality agreements say about the client's data?
  • Does the provider own the process records it created while serving a client, or only its own SOPs?
  • Would a client need to be told, or asked, before any related record is in scope?

Professionals and staff

  • Do CRM records, medical information logs or email include named physicians, pharmacists or investigators?
  • What have staff been told about their messages and documents being licensed?
  • Is notice or consent needed, and who sends it?

Retention and integrity

  • Regulated records must be kept complete and unaltered for set periods. Can a copy be made and processed without touching the original or its audit trail?
  • Who confirms that in writing before any export runs?
  • Are any records under a legal hold?
A sorting rule for brokers. If a record is about a patient, a molecule's secrets or a client's product, assume it is out until a lawyer says otherwise. What remains is where most licensable scope sits: procedures, training, support history, project methods, and internal discussion about the company's own operations. For the wider picture, read healthcare data and AI training and client confidentiality and data sales. General information, not legal advice.
Where to spend your time

Why mid-size service companies are often more practical targets than big pharma

The buyer programs that pay referral fees publish who they want. Their published rules point at mid-size companies, which is where much of the pharma service ecosystem sits.

30+employees, micro1's published minimum. Its referral posting says 30 to 200
20+full-time US office employees, Mode's published fit, with several years of records
$100K-$2M+micro1, "for approved data packages", as published
60 to 90 daysfor a deal to close, as practitioners cite

Big pharma

Who decides
Several committees: data governance, legal, privacy, IT security, often a global AI office as well.
What it owns outright
A great deal, but much of it is patient data, trade secrets or partner content, and every scope question takes a review cycle.
Fit with published rules
Far above every minimum. Size is not the problem; the path to a signature is.
What a payout means
A published range of six or seven figures is small next to its budgets, so the deal competes for attention and often loses.
Your role as broker
Rarely needed. A company this size can approach AI labs directly.

Mid-size pharma services company

Who decides
Often a founder, CEO or COO, with outside counsel and a quality lead.
What it owns outright
Its SOP library, training, method know-how, support history and internal discussion, once client records are set aside.
Fit with published rules
Often inside micro1's 30 to 200 band and above Mode's 20 US office staff, with many years of records.
What a payout means
A meaningful line in the year's revenue, which keeps the project moving through the 60 to 90 days a deal takes.
Your role as broker
Real: finding the company, qualifying it, and introducing it to a program that fits.

Buyer facts as published, checked 7 October 2026: micro1 "$100K-$2M+ for approved data packages", Mode "$100K-$5M". These are published ranges, not offers. The trade-off is real: a mid-size service company has less data than a global drug maker, and some of what it holds belongs to clients. Smaller, owned and decidable usually beats larger, shared and stuck.

Scored preview

US labs, CROs and life-science companies: how to read the free preview

The free preview of the list shows 5 visible rows. They are companies checked for this industry, and they can change, so we do not copy them onto this page. See the live preview for the rows as they stand today. The list itself can be bought once, from $199 a list (the 3,000+ highest-scored companies), as a snapshot with no updates. The API plans do not include lists; they score the domains you send, which is how you check pharma companies you find outside the file.

Each visible row shows the company website, its AI Data Value Score and grade, its activity status, the year it came online and the data it likely holds. Every company in the preview carries the category "Life sciences, pharma and labs". Live counts for the list are on the lists page, because the list grows as more companies pass our checks.

Notice what the preview does not do: it does not sort companies into the five segments above. A domain and a category do not tell you whether a company is a manufacturer, a service provider, a software vendor or a supplier to labs, and we will not guess on a public page. That sorting is your first job as a broker, and it takes a few minutes per company on its own website. The value of the list is the order: it puts the companies that likely hold the most of what AI buyers want first, with their history and status beside them.

Look also at the dates in the online since column. Long, continuous history is one of the nine factor groups in the score, and it lines up with what Mode publishes: several years of records. A company that has run a support desk for two decades has a deeper archive than one that opened last year, even if both look similar today.

What the one-time file holds

The one-time download holds the top 3,000+ by AI Data Value Score, selected from 22,954 US domains in this sector of our index, which is where most brokers start: the strongest candidates, already in order. Rank is not everything in pharma services, where a small bioanalytical lab, a regulatory consultancy or a software supplier to labs can be an easier partner than a larger name, even if its score sits further down. If you plan to tag segments yourself and push service providers up, start from the file, then score the providers you already know that are not in it: one at a time in the demo, or in batches of up to 100 domains through the API on any plan.

Company-level information from public signals only. Scores are estimates, not valuations or offers, and do not mean a company wants to sell data.

Activity status and the score

How the AI Data Value Score and activity status shorten a pharma prospect list

Every AI Data Value Score gives a company a score from 0 to 100, a grade, the data it likely holds, its history and an activity status. The nine factor groups are history, scale, knowledge assets, operational systems, customer systems, organization, industry value, expertise and activity status.

Active

Operating company

The company looks like it is trading normally. Next step: qualify it against published buyer rules, then work out who signs.

Winding down or acquired

Decision may have moved

Pharma services consolidate often. If a lab or CRO was bought, the parent may now control the systems and the data policy. Find out who owns the records before you pitch anyone.

Parked

No working company site

The domain no longer presents an operating company. Treat it as history, not a target, unless you can establish who controls whatever records survive.

Unreachable

Could not be read

The site could not be reached when it was checked. Check again later before drawing any conclusion about the company.

From segment to shortlist in five steps

A working order for a broker or a data company's sourcing team, using only company-level information.

  1. Buy the list file once

    Buy the US labs, CROs and life-science list once as a CSV snapshot, from $199 a list (the 3,000+ highest-scored companies), best first. Pharma companies you found yourself go through the API in batches: up to 100 domains per call, one lookup per domain, on every plan.

  2. Filter by score and status

    Set a minimum score, keep companies marked active, and set aside anything winding down or acquired until you know who controls it now.

  3. Sort by distance from the patient

    Open each company's site and tag its segment. Push service providers, labs, software and instrument companies up; push anyone whose record is mostly patient data down.

  4. Qualify against buyer rules

    Run each survivor through check your company. It reads public pages and compares team size, location, history and systems with micro1 and Mode rules, with quotes, in about 20 seconds.

  5. Introduce through the right program

    Only with consent from someone who can speak for the company, and only through each program's own referral process. Read data referral programs for the published terms.

ExamplePOST /api/v1/score/batch
# Any plan: score up to 100 of your own domains in one call
curl -X POST -H "X-API-Key: YOUR_KEY" -H "Content-Type: application/json" \
  -d '{"domains": ["bioanalytical-lab.example", "regulatory-consult.example", "lab-software.example"]}' \
  "https://www.selldatatoai.com/api/v1/score/batch"

{
  "id": "b_(batch id)",
  "status": "done",
  "total": 3,
  "lookups_charged": 3,
  "results": [
    {
      "domain": "bioanalytical-lab.example",
      "status": "done",
      "result": {
        "data_asset_score": 63,
        "grade": "C",
        "status": "active",
        "history": { "first_seen_year": 2004, "years_online": 22 },
        "likely_data_assets": [
          { "type": "knowledge_base", "confidence": "high" },
          { "type": "research_records", "confidence": "medium" }
        ]
      }
    }
    (two more results, in the order you sent them)
  ]
}
Example with fictional .example domains and invented values, shortened. Each valid, unique domain counts as one lookup, up to 100 domains per call. If results are still pending, poll the batch id until the status is done; polling is free. Field reference: API documentation.
Plans

What each API plan gives you

Last updated: 8 October 2026. Payment by PayPal or card. The plans score the domains you send and differ only by lookups; batch scoring of your own domain lists is on every plan. No plan includes a company list: the list is a one-time file, set out under the plans. Your API key appears in your dashboard after payment, not by email. Full details on pricing.

Basic

$99 a month
  • 5,000 lookups a month
  • Score any company you find yourself, including pharma companies outside the list
  • Batch scoring of your own domain lists, up to 100 domains per call
  • Score, grade, likely data assets, history and activity status in every response
Choose Basic

Pro

$299 a month
  • 25,000 lookups a month
  • Batch scoring of your own domain lists, up to 100 domains per call
  • The same response fields as Basic; only the lookups differ
Choose Pro

Scale

$799 a month
  • 100,000 lookups a month
  • Batch scoring of your own domain lists, up to 100 domains per call
  • The same response fields as Basic; only the lookups differ
Choose Scale

Company lists: sold only as one-time files, with or without a plan. Each list you choose holds the top 3,000+ companies of a US sector by AI Data Value Score, and more lists cost less each.

Purchase1 list2 lists3 lists5 listsEach further listAll 21 lists
One-time price$199$379$539$799+$199$3,900

The checkout shows the exact price for the lists you pick. Download links are emailed right after payment, valid 30 days with 10 downloads per file. Each file is a snapshot with no updates. To score pharma companies that are not in the file, send their domains to the API in batches on any plan.

Buy the US labs, CROs and life-sciences list: from $199 a list (the 3,000+ highest-scored companies)

Want to see a result first? The AI Data Value Score demo scores a limited number of companies a day.

Before you introduce

A broker's checklist for pharma and pharma services targets

Referral fees in this market are published and large. micro1 publishes "earn $50,000" per referred company with "no cap", paid after onboarding plus a minimum revenue threshold. Mode publishes "$50K per referral". All as published, checked 7 October 2026.

The terms matter as much as the amounts. micro1's terms give it sole discretion over every referred company, allow clawbacks, forbid sharing payouts with the company you refer, and forbid presenting yourself as micro1's partner. Read each program's terms before your first introduction, not after your first close.

Pharma adds its own layer. A company that runs regulated systems will ask hard questions early, and a broker who cannot answer them loses the room. Arrive knowing which segment the company is in, which of the six record families it likely holds, which of those are off limits, and which buyer program's published rules it meets. That is what the checklist covers, and none of it needs anything beyond company-level information.

One more point of conduct. You never handle the data. The company signs with the buyer, scopes the records with the buyer, and gets paid by the buyer. Your job ends at a qualified, consented introduction. For the roles in this market, read what is an AI data broker.

Ten checks before you introduce a pharma company

  • Segment tagged: big pharma, specialty, generics, CDMO or CMO, or services.
  • Activity status is active, and no parent company has taken over the decision.
  • Team size and US presence meet the program you plan to use.
  • Several years of records, not just a long-lived domain.
  • The likely data assets include records the company owns, such as support or SOPs.
  • Patient data, trade secrets and submissions flagged as questions for counsel.
  • Client and sponsor agreements named as the first document to read.
  • Consent from someone authorized to speak for the company.
  • Not already in the program's system as a lead or client.
  • No promise of acceptance or price, and no share of your fee offered to the company.
FAQ

Questions about pharmaceutical companies as data partners

Does this page list every pharmaceutical company in the USA?

No. This page maps the segments of US pharma and the records each one keeps, for people who find data partners. The company list closest to pharma is our US labs, CROs and life-science companies list, one of 26 US industry lists we sell, and a free preview of it is public. Any pharmaceutical company outside that list can be scored one at a time in the demo or through the API.

Which pharmaceutical companies make the most practical AI data partners?

Often mid-size service companies rather than the largest drug makers: CROs, testing and bioanalytical labs, CDMOs, regulatory and quality consultancies, and software and instrument suppliers to labs. They tend to own their procedures, training and support history outright, they sit inside the team sizes buyer programs publish, and a founder or COO can usually decide.

Can a pharmaceutical company sell patient or clinical trial data to AI companies?

Treat it as out of scope until the company’s own counsel says otherwise. Trial participant data, adverse event cases and patient inquiries are covered by consent forms, contracts and health privacy law, and much trial data belongs to the sponsor rather than the company holding it. This page lists the questions to ask; it is general information, not legal advice.

Why not start with big pharma?

Big pharma holds the deepest records but has the longest path to a yes: central data governance, internal AI programs, global privacy teams and a payout that is small next to its budgets. When a company that size licenses data, it can talk to AI labs directly and has little need for an introduction.

What do the API plans include, and how do I get the list itself?

The API plans score the domains you send and differ only by lookups. Basic $99 a month: 5,000 lookups. Pro $299 a month: 25,000 lookups. Scale $799 a month: 100,000 lookups. Batch scoring of your own domain lists is on every plan, up to 100 domains per call, one lookup per domain. No plan includes a company list. The US labs, CROs and life-science list is sold only as a one-time file, from $199 a list (the top 3,000+ companies of the sector by AI Data Value Score), a CSV snapshot with no updates; download links are emailed right after payment, valid 30 days with 10 downloads per file. Payment is by PayPal or card; on a plan, the API key appears in your dashboard after payment.

What does the activity status in an AI Data Value Score tell me?

Whether the company looks active, winding down or acquired, parked, or unreachable. In pharma services, where companies are often bought and merged, it tells you early whether the decision may now sit with a parent company, before you spend time on an introduction.

Does a high AI Data Value Score mean the company wants to sell its data?

No. The score is an estimate from public signals of how valuable the data a company is likely to hold is to AI buyers. It is not a valuation, not an offer and not a sign that the company wants to sell. Use it to decide which companies to look at first, then qualify each one.

Do you provide contacts or named people at these companies?

No. Everything we provide is company level: the domain, the score, the grade, the data the company likely holds, its history and its activity status. We do not provide names, emails or phone numbers.

Start with the companies that can say yes

See the free preview of the scored labs and CROs list, score any pharma company in the demo, and qualify a target against published buyer rules before you spend an hour on it. When you want more than the preview, buy the list once, from $199 a list (the 3,000+ highest-scored companies), and score the companies you find outside it through the API in batches.